Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLK NASDAQ:BMEA NASDAQ:IVVD NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.25 million shsN/ABMEABiomea Fusion$1.92+4.9%$1.78$1.29▼$13.07$114.26M-0.13561,492 shs492,208 shsIVVDInvivyd$1.14+14.3%$0.77$0.35▼$2.74$136.96M0.5513.39 million shs7.59 million shsSPROSpero Therapeutics$2.15+0.5%$2.31$0.51▼$3.22$120.99M1.46528,207 shs175,498 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%0.00%-50.14%BMEABiomea Fusion0.00%-1.54%+17.79%-22.89%-74.90%IVVDInvivyd0.00%+17.16%+52.00%+15.22%+34.10%SPROSpero Therapeutics0.00%+3.86%-0.92%-14.00%+64.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.25 million shsN/ABMEABiomea Fusion$1.92+4.9%$1.78$1.29▼$13.07$114.26M-0.13561,492 shs492,208 shsIVVDInvivyd$1.14+14.3%$0.77$0.35▼$2.74$136.96M0.5513.39 million shs7.59 million shsSPROSpero Therapeutics$2.15+0.5%$2.31$0.51▼$3.22$120.99M1.46528,207 shs175,498 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%0.00%-50.14%BMEABiomea Fusion0.00%-1.54%+17.79%-22.89%-74.90%IVVDInvivyd0.00%+17.16%+52.00%+15.22%+34.10%SPROSpero Therapeutics0.00%+3.86%-0.92%-14.00%+64.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.33Hold$3.00811.58% UpsideBMEABiomea Fusion 3.17Buy$14.80670.83% UpsideIVVDInvivyd 3.25Buy$3.18179.24% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00132.56% UpsideCurrent Analyst Ratings BreakdownLatest ALLK, IVVD, SPRO, and BMEA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025BMEABiomea FusionJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/28/2025BMEABiomea FusionJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/27/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/25/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $1.008/15/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $3.008/11/2025BMEABiomea FusionCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $7.008/6/2025BMEABiomea FusionScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Outperform$30.00 ➝ $10.008/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/5/2025BMEABiomea FusionOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/21/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.007/16/2025BMEABiomea FusionCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $9.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/ABMEABiomea FusionN/AN/AN/AN/A$1.42 per shareN/AIVVDInvivyd$25.38M5.40N/AN/A$0.56 per share2.04SPROSpero Therapeutics$47.98M2.52N/AN/A$0.85 per share2.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%N/ABMEABiomea Fusion-$138.43M-$3.03N/AN/AN/AN/A-243.95%-140.74%11/4/2025 (Estimated)IVVDInvivyd-$169.93M-$0.92N/A10.36N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$0.98N/AN/AN/A-110.35%-120.27%-55.61%11/13/2025 (Estimated)Latest ALLK, IVVD, SPRO, and BMEA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/12/2025Q2 2025SPROSpero Therapeutics-$0.38-$0.03+$0.35-$0.03$11.00 million$14.19 million8/5/2025Q2 2025BMEABiomea Fusion-$0.59-$0.51+$0.08-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08BMEABiomea FusionN/A3.683.68IVVDInvivydN/A1.331.33SPROSpero TherapeuticsN/A3.973.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%BMEABiomea Fusion96.72%IVVDInvivyd70.36%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%BMEABiomea Fusion18.42%IVVDInvivyd25.40%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableBMEABiomea Fusion5059.51 million48.55 millionOptionableIVVDInvivyd100120.14 million89.63 millionOptionableSPROSpero Therapeutics15056.28 million53.18 millionOptionableALLK, IVVD, SPRO, and BMEA HeadlinesRecent News About These CompaniesInsider Selling: Spero Therapeutics (NASDAQ:SPRO) Director Sells 6,572 Shares of StockSeptember 5 at 9:44 AM | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Director Sells $12,946.84 in StockSeptember 4 at 6:34 AM | insidertrades.comAnson Funds Management LP Has $5.50 Million Position in Spero Therapeutics, Inc. $SPROAugust 26, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above 200-Day Moving Average - Here's What HappenedAugust 25, 2025 | marketbeat.comDown 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a TurnaroundAugust 19, 2025 | zacks.comSpero Therapeutics (NASDAQ:SPRO) Releases Earnings Results, Beats Expectations By $0.32 EPSAugust 14, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 13, 2025 | finanznachrichten.deSpero Therapeutics Reports Q2 2025 Results and Trial SuccessAugust 13, 2025 | msn.comSpero Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comSpero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comSpero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comSpero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025August 5, 2025 | globenewswire.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28, 2025 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | insidermonkey.comGSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMCMay 30, 2025 | pharmabiz.comPSpero Therapeutics rockets on positive Phase III study for tebipenem HBrMay 29, 2025 | thepharmaletter.comTSpero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 MilestoneMay 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Why Sprouts Farmers Market is Buying $1 Billion of Its Own StockBy Gabriel Osorio-Mazilli | August 25, 2025Improving Fundamentals Drive New Buybacks for 3 Strong PerformersBy Leo Miller | August 29, 2025ALLK, IVVD, SPRO, and BMEA Company DescriptionsAllakos NASDAQ:ALLKAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Biomea Fusion NASDAQ:BMEA$1.92 +0.09 (+4.92%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.92 +0.00 (+0.05%) As of 09/5/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Invivyd NASDAQ:IVVD$1.14 +0.14 (+14.29%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.12 -0.02 (-1.75%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Spero Therapeutics NASDAQ:SPRO$2.15 +0.01 (+0.47%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.15 +0.00 (+0.05%) As of 09/5/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
